Erratum: Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702)

Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, G. Ostoros, Vladimir Hanes

Research output: Contribution to journalComment/debate

Abstract

In the original version of this article (1), Fig. 1 was incomplete and the "Methods" sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.

Original languageEnglish
Number of pages1
JournalClinical Cancer Research
Volume25
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this